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1. Introduction
  Primary intraocular lymphoma (PIOL) is a subset of primary 
central nervous system lymphoma (PCNSL). It is uncommon, 
but no central database exists for this disease. The Central 
Brain Tumor Registry of the U.S. recorded an incidence of 
0.46 (95% confidence interval (CI), 0.45-0.47) per 100 000 
person-years in 2004-2007[1]. The principal risk factors for 
development of primary intraocular lymphoma appear to be 
older patient age, female gender, and immunosuppression 
(primary or acquired)[2]. The lymphoma cells are usually 
aggressive diffuse large, pleomorphic B lymphocytes. 
Between 65%-90% of patient who initially present with PIOL 
alone will develop CNS lymphoma[1]. About 30% of patient 
present with unilateral involvement and 85% of patient 
had delayed involvement of second eye[3]. We report this 
rare case of rapid deterioration of progression in Primary 
intraocular lymphoma.
2. Case report
  A 73 years old Chinese lady with no medical illness 
complained of seeing floaters in the left eye for one year. 
It was associated with deterioration in the left eye vision. 
There was no eye pain, redness or prior trauma. She had no 
history of fever or unwell. No history of cough, night sweat, 
loss of appetite or weight and no history of contact with 
PTB patient. She also had no history of joint pain or skin 
changes, and was not on any medications before. She denied 
any neurological symptoms such as headache, nausea, 
vomiting or fits. She had no family history of malignancies.
Examination revealed a right eye vision of 6/24 correctable 
to 6/15 with pin-hole and a left visual acuity of 6/45 
not correctable with pin hole. Left eye anterior segment 
showed mild uveitis with keratic precipitates (Figure 1). 
Both eye intraocular pressures were normal. Funduscopy 
on presentation  revealed left vitreous clumps with vitritis 
(Figure 2) and right eye showed drusen at macula area and 
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peripherally. Optical Coherence Tomography showed no 
macular oedema. Baseline investigations including FBC, 
RP, LFT, RBS and ESR were normal. Mantoux test was 
negative. VDRL was non reactive. Chest X-ray was normal. 
Tumour markers showed normal level of Alpha Fetoprotein 
and CEA. Initial MRI brain and Orbit showed no evidence 
of brain or orbital lesions.  Ultrasound abdomen finding 
was unremarkable. Left vitrectomy and vitreous biopsy 
were performed. The result of the biopsy showed few singly 
dispersed atypical lymphoid cells, having large nuclei, 
prominent nucleoli and scanty of cytoplasm. There are few 
small mature lymphocytes in the background (Figure 3). 
Figure 1. Pigments on anterior capsule indicate previous incidence of 
anterior uveitis.
  
Figure 2. Left eye vitritis with yellowish clumps on initial 
presentation. 
   
Figure 3. (Left) Arrows showed atypical lymphoid cells display 
large round nuclei with prominent nucleoli (PAP stain×400). (Right) 
Atypical lymphoid cell, binucleated (MGG stain×400).
              
  Subsequently the clinical finding worsened and she 
developed bilateral pan uveitis. There was vitritis with 
yellowish choroidal lesions at the posterior pole. No 
vasculitic or retinitis changes noted. A diagnosis of bilateral 
primary intraocular lymphoma was made. Patient was 
co-managed with Haematologist and Neurologist team. 
However, they did not find any significant features to 
suggest CNS or haematological involvement. Therefore she 
was managed locally and received ten courses of Intravitreal 
Methotrexate of 400 毺g in 0.1 mL. Initially, she responded. 
But later she developed few episodes of recurrences. There 
were numerous new lesions with worsening of vitritis and 
multifocal choroidal lesions (Figure 4). She was not started 
on chemotherapy or radiotherapy in view of the absence of 
neurological or systemic involvement at that point. Patient 
refused for lumbar puncture for cerebral spinal fluid 
analysis. Unfortunately, five months after the diagnosis 
her general condition started to deteriorate with symptoms 
of lethargy, confusion and forgetfulness. Her vision also 
deteriorated to hand movements in both eyes. A whole 
body MRI performed which showed liver and left breast 
metastasis. She was planned for tissue biopsy. However, 
patient default her follow up. Three months later she became 
generally weak and subsequently presented to Emergency 
Department with unresponsive. A CT brain showed subdural 
bleed, white matter edema and gross midline shift which 
was suggestive of brain metastasis (Figure 5). She eventually 
succumbed to the disease.
Figure 4. Right eyes fundus photo showed large choroidal lesion and 
left eye multiple   choroiditis.
  
Figure 5. CT brain showed extensive white matter edema and gross 
midline shift.
3. Discussion
 
  Primary intraocular lymphoma (PIOL) is a variant of extra 
nodal non-Hodgkin lymphoma[4]. It has been divided 
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anatomically into vitreoretinal and uveal forms. Intraocular 
lymphoma can infiltrate any part of the eye, including the 
vitreous, retina, sub-RPE space, subretinal space and uveal 
tract. Primary vitreoretinal lymphoma is one of the subtypes, 
characterized by diffuse cellular infiltration of the vitreous 
and accumulations of lymphomatous cells in the subpigment 
epithelial space of the retina[2].  It is generally an aggressive, 
diffuse large B-cell malignancy (intermediate-grade 
lymphoma) associated with poor prognosis[4,5]. Our patient 
showed signs of this subtype of intraocular lymphoma. 
Other features include retinal vasculitis, vascular occlusion, 
exudative retinal detachment and optic atrophy. Lack of 
cystoids macular oedema (CMO) is an important diagnostic 
clue, since in true uveitis significant vitritis is almost always 
accompanied by CMO[3].
  On the other hand the uveal form is associated with 
systemic non-Hodgkin lymphoma and also with involvement 
of orbital structures. It is typically small B-cell proliferation 
(low-grade lymphoma) and usually occurs with advanced 
systemic disease. Rare cases of T-cell lymphoma with 
ocular involvement have been reported[4,5]. Mild anterior 
uveitis with cells, flare, keratic precipitates, multifocal, 
large, yellowish and solid sub-RPE infiltrates that progress 
to involve the choroid, are common signs in this subtype of 
intraocular lymphoma. Our patient also had developed signs 
of this subtype of intraocular lymphoma. Therefore, she had 
a combination of two subtypes; vitreoretinal and uveal forms.
Diagnosis of PIOL requires pathologic identification of 
atypical lymphoma cells from the vitreous or retina. 
However, the cytopathologic diagnosis is challenging 
because of the fragility and paucity of the atypical 
lymphoma cells in the vitreous. Furthermore, atypical 
lymphoma cells in the vitreous often admix with reactive 
lymphocytes, necrotic cells and debris, adding to the 
difficulty of diagnosis[5]. We manage to diagnose our patient 
by cytological analysis from vitreous sample. This is a 
sensitive and specific test to confirm the diagnosis despite 
of clinical suspicious. The correct diagnosis of intraocular 
lymphoma is often not established until late in the disease 
course. Most patients are initially misdiagnosed as having an 
idiopathic diffuse uveitis, posterior uveitis, or vitritis. Even 
with present of yellowish white chorioretinal lesions and 
vitritis, an almost pathognomonic presentation, diagnosis is 
usually delayed. As in this patient the PIOL is masquerading 
as panuveitis for a year before she presented to us. In term 
of management, this patient was treated by intraocular 
injection to avoid systemic toxicity of chemotherapy and 
risk of complication with radiotherapy as well as risk of 
partial failure. Smith and associates reported a series of 26 
eyes of 16 patients with vitreoretinal lymphoma from two 
centres using intravitreal injections of 400 毺g methotrexate 
in 0.1 mL. They used a protocol of two injections per week 
for a month as the induction phase, weekly consolidation 
injection for a month in one centre and two months in 
the other centre, and subsequently a maintenance phase 
of monthly injection to complete one year. All eyes were 
cleared clinically of lymphoma cells after a maximum of 12 
methotrexate injections. Three patients from one centre who 
had relapse in the eye were treated again using the same 
protocol, with complete remission[6]. 
  The long term prognosis for patients with PCNSL remains 
poor. Multiple factors have been found to be of significance 
in predicting outcomes and survival in patients with 
PCNSL, including age, performance status, and neurological 
function, single versus multiple lesions, and superficial 
cerebral and cerebellar hemisphere lesions versus deep 
nuclei and periventricular region lesions. The median 
survival time after detection of infiltrative intraocular lesions 
in most series is three to five months. Patients with primary 
central nervous system lymphoma with ocular involvement 
(PCNSLO) have a poor prognosis even with chemoradiation, 
and many succumb to central nervous system (CNS) disease 
within two years[3].
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